0002001011-24-000056.txt : 20240618
0002001011-24-000056.hdr.sgml : 20240618
20240618212616
ACCESSION NUMBER: 0002001011-24-000056
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240614
FILED AS OF DATE: 20240618
DATE AS OF CHANGE: 20240618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gray Nancy Ryan
CENTRAL INDEX KEY: 0001714949
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 241053840
MAIL ADDRESS:
STREET 1: C/O LIGAND PHARMACEUTICALS INCORPORATED
STREET 2: 3911 SORRENTO VALLEY BOULEVARD, STE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-06-14
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001714949
Gray Nancy Ryan
555 HERITAGE DRIVE
SUITE 200
JUPITER
FL
33458
1
0
0
0
0
Common Stock
2024-06-14
4
A
0
1252
0.0
A
6885
D
Non-Qualified Stock Option (right to buy)
80.06
2024-06-14
4
A
0
5444
0.0
A
2034-06-14
Common Stock
5444
5444
D
Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Nancy Ryan Gray
2024-06-18